Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Cytopenia 1

Interventions

AP 1903 reagent 3ON 01910 2Biopsy 2thymoglobulin 1fludarabine phosphate 1fludarabine 1epacadostat 1decitabine and cedazuridine drug combination 1cedazuridine 1angiotensin I (1-7) 1Vitamin B 12 1Therapeutics 1Specimen Handling 1Sertraline 1Pluvicto 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Interleukin-8 1Immunotherapy, Adoptive 1IDO-1 inhibitor LY3381916 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1Genetic Counseling 1Folic Acid 1Filgrastim 1Exercise 1Emapalumab 1Decitabine 1DNA 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytopenia × IDO-1 inhibitor LY3381916 × Classical hematology × Clear all
NCT01822691 2016-01-18

Phase II INCB024360 Study for Patients With Myelodysplastic Syndromes (MDS)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
15 enrolled 8 charts
Classical hematologyMyeloidOther hematologic neoplasm

Cytopenia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡